Mingtain Lai

MingTain Lai is the Chief Scientific Officer and Executive Vice President at OBI Pharma, Inc. since April 2019, leading research and development efforts in Immuno-Oncology targeting Globo Series glycosphingolipids. Responsibilities include shaping company strategy, overseeing all R&D divisions, and managing IND submissions. Prior experience includes a 24-year tenure at Merck in roles ranging from Senior Principal Scientist to Director, contributing to the development of antiviral therapies and leading significant drug discovery projects, including the NDA filing team for Doravirine. MingTain Lai holds a Ph.D. in Biochemistry from the University of Minnesota and completed postdoctoral studies at the Massachusetts Institute of Technology.